Прогностическое значение амплификациигена MYCN, делеции короткого плечахромосомы 1 и делеции длинного плеча хромосомы 11 у пациентов с нейробластомой

Александр Евгеньевич Друй; Григорий Анатольевич Цаур; Егор Валерьевич Шориков; Александр Михайлович Попов; Леонид Иосифович Савельев; Сергей Васильевич Цвиренко; Лариса Геннадьевна Фечина

Prognostic Impact of MYCN Amplification, 1p Deletion and 11q Deletion in Neuroblastoma Patients

Aleksandr Yevgenyevich Druy Institute of Medical Cell Technologies
Grigoriy Anatolyevich Tsaur Institute of Medical Cell Technologies
Yegor Valeryevich Shorikov Institute of Medical Cell Technologies
Aleksandr Mikhaylovich Popov Institute of Medical Cell Technologies
Leonid Iosifovich Savelyev Institute of Medical Cell Technologies
Sergey Vasilyevich Tsvirenko Institute of Medical Cell Technologies
Larisa Gennadyevna Fechina Institute of Medical Cell Technologies

Abstract

Neuroblastoma is characterized by wide clinical heterogeneity from tumors prone to spontaneous regression to highly aggressive disease that requires multimodal chemotherapy with autologous stem cells transplantation. Patient’s age and stage of the disease were described as prognostic factors. Different genetic aberrations were analyzed as potential predictive signs of poor outcome. MYCN gene amplification, 1p and 11q deletions are associated with aggressive tumor behavior, advanced stage of the disease and unfavorable outcome. In current report we analyzed molecular mechanisms and prognostic significance of indicated genetics abnormalities.